NZ 314

Drug Profile

NZ 314

Latest Information Update: 04 Jun 2015

Price : $50

At a glance

  • Originator Nippon Zoki
  • Class Antihyperglycaemics; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic complications

Most Recent Events

  • 05 Sep 2000 Phase-II clinical trials for Diabetic complications in Japan (Unknown route)
  • 03 Nov 1999 A study has been added to the Diabetes pharmacodynamics section
  • 16 May 1997 Preclinical data have been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top